Shire rejects £27bn takeover AbbVie bid
Shire rejected AbbVie’s latest £46.11 cash and share proposal arguing it is“fundamentally undervaluing” the company
Friday 20 June 2014
Shire has rejected a trio of possible offers worth up to £27.3 billion from a US suitor after vowing to remain independent.
The company, best-known for its Vyvanse blockbuster treatment for attention deficit hyperactivity disorder, faced the approaches from pharmaceuticals firm AbbVie while AstraZeneca was fending off a £63 billion takeover attempt from Pfizer.
Shire today said it rejected AbbVie’s latest £46.11 cash and share proposal, a 23 per cent premium to last night’s close, as “fundamentally undervaluing” the company.
But the shares leapt 14 per cent, or 522p, to 4260p as investors weighed into company, which has long been seen as a takeover target.
Chairman Susan Kilsby underlined the company’s growth prospects with a new target to double annual product sales, which account for the bulk of revenues, to $10 billion (£5.9 billion) by 2020, and urged shareholders to “take no action”.
She said: “The board believes the proposal fundamentally undervalued Shire and its prospects and that as an independent company Shire’s focused growth strategy will continue to deliver significant shareholder value and patient benefits.”
Shire stressed its 19 per cent rise in product sales growth over the past year, and the strong growth of its rare diseases unit, bolstered by the $4.2 billion deal for US company ViroPharma last year. Shire is building up the division as it faces more generic competitors to its ADHD drugs. “Shire has a long track record of delivering for shareholders and addressing unmet patient needs,” she added.
Panmure Gordon analyst Savvas Neophytou said Shire could be worth as much as £55 a share and noted the “distinct lack of the word ‘final’” anywhere in AbbVie’s announcement despite talks no longer taking place.
He added: “Shire’s rare diseases business is one of the hottest assets in biopharmaceuticals... Given the company’s growth characteristics, a premium valuation is warranted in our view.” The company also highlighted total shareholder returns of 99 per cent over the past year, including reinvested dividends.
Though London listed, Shire is domiciled for tax purposes in Ireland. If successful in the approach AbbVie planned to move its tax base to the UK under an inversion structure to cut its US tax bill, similar to Pfizer’s plans for Astra. Shire’s board also had “concerns regarding the execution risks associated with the proposed inversion structure”.
- 2 Why this father didn’t hide his daughter’s heroin overdose in her obituary
- 3 Company breaks open Apple Watch to discover what it says is 'planned obsolescence'
- 5 The most powerful passports in the world
Nepal earthquake in pictures: Photos show devastation caused by 7.8 magnitude earthquake
Smartphones are making children borderline autistic, says psychiatrist
Nepal earthquake: The race is on to help thousands trapped under rubble around Kathmandu, while remote villages face a long wait for help
Royal baby: Live updates as superbug closes ward at St Mary's Hospital where Duchess of Cambridge is due to give birth
Teaching profession headed for crisis as numbers continue to drop and working lives become 'unbearable'
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband
The sickening truth about food banks that the Tories don't want you to know
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
General Election 2015: Britain would become a 'communist dictatorship' under Ed Miliband and Nicola Sturgeon, claims wife of Michael Gove
iJobs Money & Business
£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50000 - £55000 per annum: Ashdown Group: Business Analyst - Financial Service...
£18000 - £23000 per annum + OTE £45K: SThree: At SThree, we like to be differe...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is the o...